Implanet - Road Show in New York on 4/26 & Boston on 4/27
New York, April 15, 2016 (Newswire.com) - Ludovic Lastennet, CEO and David Dieumegard, CFO of Implanet will be in New York on Tuesday, April 26 and in Boston on Wednesday, April 27 to present the group’s results and strategy. Based in Bordeaux, Implanet is listed on Euronext Paris with a market cap. of ~ $20m. Founded in 2007, Implanet is a medical devices company that manufactures first in class implants for orthopedic surgery. Its flagship product, the JAZZ device (FDA approved), treats spinal pathologies.
Implanet just received FDA & CE Mark Green Light for a new device – JAZZ Lock. This major breakthrough extends its platform to the cervical spine. Jazz Lock® is the first of an innovative range of band products designed for degenerative spine disorder surgery. This device allows Implanet to broaden its activity to the cervical spine, a market of more $200m on a global basis. Based on the polyester sublaminar braid platform, Jazz Lock® eliminates the mechanism’s locking screw and connecting rod, thanks to a proprietary fastening locking system. The group expects to have an effective dual listing on the OTCQX soon and has a US subsidiary based in Boston. With about 50 employees, the group has a strong and experienced management team, led by CEO Ludovic Lastennet who worked previously for Danaher and Stryker before co-founding Implanet.
Founded in 2007, Implanet is an Innovative Medical Device Firm, with FDA approved products. The Group just Received new FDA & CE Mark Green Light for a novel Device, JAZZ Lock. This Major Breakthrough Extends its Platform to the Cervical Spine.
Ludovic Lastennet, CEO
The group has more than 12,000 JAZZ Band implanted since its launch. The growth of its spine unit results from the adoption by spine surgeons over the last 2 years, in France and in the US. “JAZZ Band” competitive advantages are for Medicare - a reduction in surgical cost, less blood loss for patients and less Operating Room time for Surgeon, while demonstrating improvement in Sagittal Balance of patient afterward. JAZZ Band address a global market of $2bn. 2015 sales were €6.7m – with a strong growth coming from JAZZ platform. The group has a strong balance sheet with €7m in cash at year-end 2015. Let me know if interested in a meeting.
Contact: Pascal Nigen – Managing Partner, Alpha Bronze
Phone: +1 (917) 385-2160; pnigen@alphabronzellc.com
Source: Implanet